13F reference period
Q3 2026
Security Snapshot
Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) Institutional Ownership
CUSIP: 74907L409
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
9
Shares (Excl. Options)
786.32K
Full value: 786,321 · shares · 30 Sep 2026Price
$4.56
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
- Symbol
- QNRX on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 786,321
- Total 13F value
- $3,585,624
- Portfolio coverage rank
- 0%
- Share change
- +413,041
- Value change
- +$1,856,866
- Number of holders
- 9
- Shares outstanding
- 4,807,682
- SEC-reported price per share
- $4.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- QNRX - Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share is tracked under CUSIP 74907L409.
- 9 institutions reported positions in Q3 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 19 to 9 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$6.29M
Full value: $6,289,055 · USD · 30 Jun 2026.$3.59M
Full value: $3,585,624 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 9 institutions filings for Q3 2026.
Security key
74907L409
13F reference period
Q3 2026
13F holders
9
13D/G owners
8
CIK / CUSIP context first
Open Q3 2026 holders
QNRX full holder history
Quoin Pharmaceuticals Ltd. SEC filings
Quoin Pharmaceuticals Ltd. company facts
Quoin Pharmaceuticals Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74907L409:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
QNRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC | 5.5% | +18% | $22,755,775 | +$7,279,879 | 3,850,385 | +47% | Integrated Core Strategies (US) LLC | 26 May 2026 |
| Stonepine Capital Management, LLC | 11% | +7% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| Woodline Partners LP | 9.5% | $38,298,838 | 2,785,370 | Woodline Partners LP | 31 Dec 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | $7,049,313 | 1,081,183 | Armistice Capital, LLC | 31 Mar 2025 | |||
| Ikarian Capital, LLC | 4.4% | -63% | $1,436,343 | 211,538 | 0% | Ikarian Capital, LLC | 30 Sep 2026 | |
| ADAR1 Capital Management, LLC | 4.9% | -29% | $609,067 | +$264,346 | 102,883 | +77% | ADAR1 Capital Management GP, LLC | 31 Mar 2026 |
| Aberdeen Group plc | 4.2% | -53% | $491,250 | 75,000 | 0% | Aberdeen Group plc | 01 Apr 2026 | |
| Resolute Capital Asset Partners LLC | 8.5% | $671,000 | 50,000 | Resolute Capital Asset Partners LLC | 10 Oct 2025 |
As of 30 Sep 2026,
9
institutional investors reported holding
shares of
Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX).
This represents
16%
of the company’s total
outstanding shares.
786.32K
Full value: 786,321 · shares · 30 Sep 20264.81M
Full value: 4,807,682 · shares · Stored outstanding share count13F concentration
Top 11 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
16%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 5.3% | 252,434 | +27% | 0.96% | $1,151,099 |
| AIGH Capital Management LLC | 4.9% | 236,234 | +237% | 0.12% | $1,077,227 |
| Nantahala Capital Management, LLC | 4.9% | 236,234 | 0.06% | $1,077,227 | |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 1% | 50,000 | 0.16% | $228,000 | |
| MORGAN STANLEY | 0.17% | 8,000 | 0% | 0% | $36,480 |
| GAMMA Investing LLC | 0.06% | 3,116 | +610% | 0% | $14,209 |
| Arax Advisory Partners | 0% | 171 | 0% | $780 | |
| SBI Securities Co., Ltd. | 0% | 128 | -64% | 0% | $584 |
| NISA INVESTMENT ADVISORS, LLC | 0% | 4 | 0% | $18 | |
| Aberdeen Group plc | 0% | 0 | -100% | $0 | |
| Birchview Capital, LP | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q3 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 786,321 | $3,585,624 | +$1,856,866 | $4.56 | 9 |
| 2026 Q2 | 1,299,393 | $6,289,055 | +$392,231 | $4.84 | 19 |
| 2026 Q1 | 1,184,710 | $7,819,079 | +$1,428,993 | $6.60 | 20 |
| 2025 Q4 | 842,827 | $12,161,983 | +$12,140,475 | $14.43 | 18 |
| 2025 Q3 | 1,491 | $10,716 | -$9,379 | $7.09 | 4 |
| 2025 Q2 | 2,537 | $23,400 | +$22,428 | $9.23 | 6 |
| 2025 Q1 | 108 | $24 | +$24 | $0.22 | 1 |